Farringdon Capital Ltd. purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,432 shares of the company's stock, valued at approximately $322,000.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JFS Wealth Advisors LLC raised its holdings in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in Cencora during the fourth quarter worth $30,000. Kentucky Trust Co acquired a new stake in Cencora during the fourth quarter worth approximately $33,000. Householder Group Estate & Retirement Specialist LLC grew its stake in Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after acquiring an additional 69 shares during the period. Finally, WASHINGTON TRUST Co raised its holdings in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.
Cencora Stock Down 0.5 %
Shares of COR traded down $1.47 during mid-day trading on Thursday, reaching $283.24. 475,818 shares of the stock traded hands, compared to its average volume of 1,704,943. The stock has a fifty day simple moving average of $266.42 and a 200 day simple moving average of $248.28. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $296.65. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm has a market cap of $54.93 billion, a price-to-earnings ratio of 40.29, a P/E/G ratio of 1.31 and a beta of 0.55.
Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.
Cencora Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is presently 31.29%.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the company. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Evercore ISI raised their price target on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. raised their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Wells Fargo & Company raised their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Finally, Morgan Stanley set a $288.00 price target on Cencora in a research note on Tuesday, April 15th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Cencora has a consensus rating of "Moderate Buy" and a consensus target price of $284.55.
Read Our Latest Stock Analysis on COR
Insiders Place Their Bets
In other news, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the sale, the chief executive officer now owns 47,582 shares of the company's stock, valued at approximately $13,766,900.06. The trade was a 9.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock valued at $13,580,967 over the last 90 days. 10.80% of the stock is owned by company insiders.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
